Core Viewpoint - Enhua Pharmaceutical has entered into an exclusive commercial cooperation agreement with Green Leaf Pharmaceutical and its subsidiary, granting Enhua exclusive rights to promote and sell three long-acting antipsychotic injectable products in mainland China until December 31, 2035 [1] Group 1: Agreement Details - Enhua's subsidiary, Enhua Hexin, will pay a non-refundable licensing fee of $20 million to Green Leaf Pharmaceutical and Green Leaf Jiaao [1] - The agreement includes three products: injectable risperidone microspheres (II), paliperidone palmitate injection (II), and paliperidone palmitate injection from Green Leaf Jiaao [1] - Enhua is required to achieve a minimum sales target of 2.7 billion RMB (including tax) for the cooperative products between 2026 and 2035 [1] Group 2: Financial Implications - Green Leaf Pharmaceutical and Green Leaf Jiaao will pay Enhua service fees based on the procurement and sales performance of the licensed products [1]

Core Viewpoint - Enhua Pharmaceutical has entered into an exclusive commercial cooperation agreement with Green Leaf Pharmaceutical and its subsidiary, granting Enhua exclusive rights to promote and sell three long-acting antipsychotic injectable products in mainland China until December 31, 2035 [1] Group 1: Agreement Details - Enhua's wholly-owned subsidiary, Enhua Hexin, will receive exclusive rights for the promotion, sales, and other commercialization activities of three products: injectable risperidone microspheres (II), paliperidone palmitate injection (II), and paliperidone palmitate injection from Green Leaf Jiaoda [1] - The agreement requires Enhua Hexin to make a one-time, non-refundable payment of $20 million to Green Leaf Pharmaceutical and Green Leaf Jiaoda [1] - Enhua Hexin is obligated to achieve a total sales revenue of no less than 2.7 billion RMB (including tax) for the cooperative products between 2026 and 2035 [1] Group 2: Transaction Nature - The transaction does not constitute a related party transaction and does not qualify as a major asset restructuring [1]